PALISADE BIO, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PALISADE BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $20.00K, a 566.67% increase year-over-year.
- PALISADE BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $16.00K.
- PALISADE BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $0.00.
- PALISADE BIO, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $3.00K, a 72.73% decline year-over-year.
- PALISADE BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $19.00K, a 72.73% increase from fiscal 2024.
- PALISADE BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $11.00K, a 35.29% decline from fiscal 2023.
- PALISADE BIO, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $17.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $20.00K 10-Q · filed 2026-08-10 | |
| 2025-12-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $19.00K 10-K · filed 2026-03-20 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | |
| 2025-06-30 | $3.00K 10-Q · filed 2026-08-10 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $11.00K 10-K · filed 2026-03-20 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | |
| 2024-06-30 | $11.00K 10-Q · filed 2025-08-11 | |
| 2023-12-31 | $17.00K 10-K · filed 2025-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |